Table 2.
Analysis of the changes in body mass index according to the characteristics of coinfection and disease characteristics by HIV or leprosy
| Predictor variables | βx (95% CIa)P | Sensitivity analysis |
|---|---|---|
| Groups | ||
| HIV/leprosy | Reference groupc | |
| Leprosy | −1.16 (−2.83, 0.52)P>0.05 | −0.80 (−2.42, 0.81)P>0.05 |
| HIV | −2.40 (−4.08, −0.71)P=0.006 | −2.67 (−4.30, −1.04)P=0.002 |
| Sex | ||
| Male | Reference groupc | |
| Female | −1.42 (−2.81, −0.02)P<0.046 | −1.37 (−2.76, 0.19)P>0.05 |
| Physical activity | ||
| Non-practising | Reference groupc | |
| Practising | −0.32 (−1.97, 1.32)P>0.05 | −0.41 (−2.00, 1.16)P>0.05 |
| Sex | ||
| Male | Reference groupd | |
| Female | −1.61 (−3.30, 0.05)P>0.05 | −1.53 (−3.11, 0.37)P>0.05 |
| CD4 (cell/mm3) | 0.00 (−0.00, 0.00)P>0.05 | 0.00 (−0.00, 0.00)P>0.05 |
| Time to HIV diagnosis | 0.10 (−0.30, 0.50)P>0.05 | 0.10 (−0.27, 0.47)P>0.05 |
| Time with HAART | 0.00 (−0.45, 0.44)P>0.05 | −0.11 (−0.53, 0.30)P>0.05 |
AIDS=acquired immunodeficiency syndrome, BMI=body mass index, CI=confidence interval, HIV=human immunodeficiency virus, HAART=highly active antiretroviral therapy. aReliability interval of 95%. bSensitivity analysis given by the removal of outliers (n=2) in the HIV group. cInitial analysis: n=90, R2=0.11, P=0.031; sensitivity analysis: n=88, R2=0.14, P=0.011. dInitial analysis: n=90, R2=0.22, P=0.016; adjusted analysis: n=88, R2=0.25, P=0.008